Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
Group A CP,
51 pts
DEMOGRAPHICS Male/Female 35/16 37/8
PRIMARY
TREATMENT
SECOND-LINE
TREATMENT
AND SURVIVAL
Median age 63 64
PS 0-1/PS 2 40/11 36/9
epitheliod/biphasic/
sarcomatoid/unspec
Group B C-GILI,
45 pts
42/2/4/3 32/8/4/2
ORR, % 48.9 50.0
PFS (months,
median)
% of pts with any
grade ≥ 3 toxicity
% of pts crossingover
to alternative
combination
10.6 8.6
51.1 55.6
77.8 61.1
OS (months, median) 20.6 18.6
POSTER SESSION 3 – P3.03: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL
CANCER/OTHER THORACIC
MESOTHELIOMA CLINICAL –
WEDNESDAY, DECEMBER 7, 2016
P3.03-031 DEFINITIVE RADIATION THERAPY IS ASSOCIATED WITH
IMPROVED SURVIVAL IN NON-METASTATIC MALIGNANT PLEURAL
MESOTHELIOMA
Kenneth Rosenzweig 1 , Nisha Ohri 2 , Andrea Wolf 3 , Jorge Gomez 4 , Raja Flores 3 ,
Emanuela Taioli 5
1 Radiation Oncology, Mount Sinai, New York/NY/United States of America,
2 Department of Radiation Oncology, ICAHN School of Medicine at Mount Sinai,
New York/NY/United States of America, 3 Department of Thoracic Surgery, The
Mount Sinai Health System, New York/NY/United States of America, 4 Tisch Cancer
Institute, ICAHN School of Medicine at Mount Sinai, New York/NY/United States of
America, 5 Department of Population Health Science and Policy, ICAHN School of
Medicine at Mount Sinai, New York/NY/United States of America
Background: To analyze rates of definitive radiation therapy (RT) utilization
for malignant pleural mesothelioma (MPM) and evaluate the association
between RT and overall survival (OS). Methods: The National Cancer Data
Base (NCDB) was queried to identify patients with non-metastatic MPM
diagnosed between 2004 and 2013. Definitive RT was defined as receipt
of 40-65 Gy of external beam radiation therapy to the chest wall, lungs, or
pleura. Multivariate logistic regression was performed to identify predictors
of RT receipt. OS was estimated using the Kaplan-Meier method. Cox
proportional hazards models were used to identify predictors of mortality.
Propensity score matching was performed to verify the effect of definitive RT
on OS. Results: Among 14,090 MPM patients, 3.6% received RT. Younger age,
lower co-morbidity score, private insurance, surgical resection, and receipt
of chemotherapy were associated with increased RT utilization. Patients
who received RT had higher crude 2 and 5-year OS rates (33.9% and 12.6%,
respectively) compared to patients who did not (19.5% and 5.3%, respectively;
p